La faiblesse des négociations du soin entre professionnels et avec les proches de patients hospitalisés à la suite d?un AVC grave, Les négociations du soin, pp.235-246, 2014. ,
Survenue d?un accident ischémique cérébral chez un patient en fibrillation atriale sous anticoagulant oral : que faire de plus ?, La Presse Médicale, vol.43, issue.7-8, pp.784-788, 2014. ,
, Annexe 2. Problèmes concernant les données analysées à la section 4.6, 2007.
Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol, J Thromb Thrombolysis. févr, vol.41, issue.2, pp.293-300, 2016. ,
New developments in anticoagulants: Past, present and future, Thrombosis and Haemostasis, vol.117, issue.07, pp.1283-1288, 2017. ,
New developments in anticoagulants: Past, present and future, Thrombosis and Haemostasis, vol.117, issue.07, pp.1283-1288, 2017. ,
An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention, American Heart Journal, vol.171, issue.1, pp.14-24, 2016. ,
Les anticoagulants oraux directs (AODs) chez le sujet âgé : données de pharmacovigilance sur le territoire national, Les cahiers de l'année gérontologique, vol.7, issue.3, pp.98-102, 2015. ,
Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Clinical and Applied Thrombosis/Hemostasis, vol.15, issue.1_suppl, pp.9S-16S, 2009. ,
Answer: covfefe? Play <cite>Science</cite>?s election 2020 crossword puzzle!, Science, 2020. ,
Structure-based design of novel potent nonpeptide thrombin inhibitors, J Med Chem. 25 avr, vol.45, issue.9, pp.1757-66, 2002. ,
Dabigatran Inhibits Both Clot-Bound and Fluid Phase Thrombin In Vitro: Effects Compared to Heparin and Hirudin., Blood, vol.110, issue.11, pp.3998-3998, 2007. ,
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans, Drug Metabolism and Disposition, vol.36, issue.2, pp.386-399, 2007. ,
Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.30, issue.10, pp.1885-1889, 2010. ,
Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects, Clinical Pharmacokinetics, vol.47, issue.1, pp.47-59, 2008. ,
Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate, Clinical Pharmacokinetics, vol.49, issue.4, pp.259-268, 2010. ,
Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment, The Journal of Clinical Pharmacology, vol.48, issue.12, pp.1411-1419, 2008. ,
A specific antidote for dabigatran: functional and structural characterization, Blood. 2 mai, vol.121, issue.18, pp.3554-62, 2013. ,
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran, Thromb Haemost. mai, vol.113, issue.5, pp.943-51, 2015. ,
Idarucizumab for Dabigatran Reversal, New England Journal of Medicine, vol.373, issue.6, pp.511-520, 2015. ,
,
, Dabigatran Reversal with Idarucizumab, New England Journal of Medicine, vol.377, issue.17, pp.1690-1692, 2017.
Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro, Thrombosis and Haemostasis, vol.101, issue.04, pp.780-782, 2009. ,
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor, Journal of Thrombosis and Haemostasis, vol.3, issue.3, pp.514-521, 2005. ,
Les anticoagulants en France en 2012 : Etat des lieux et surveillance. Juillet 2012, Sang thrombose vaisseaux, vol.24, issue.9, pp.416-439, 2012. ,
FEVR, vol.14 ,
,
Veille et sécurité sanitaire des toxiques ? implication des agences sanitaires ? Agence nationale de sécurité du médicament et des produits de santé (ANSM), Toxicologie Analytique et Clinique, vol.27, issue.2, pp.124-125, 2015. ,
Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): An Oral, Direct Factor Xa Inhibitor, Journal of Medicinal Chemistry, vol.48, issue.19, pp.5900-5908, 2005. ,
pellic vertisol, Dictionary Geotechnical Engineering/Wörterbuch GeoTechnik, pp.972-972, 2014. ,
pellic vertisol, Dictionary Geotechnical Engineering/Wörterbuch GeoTechnik, pp.972-972, 2014. ,
The effect of food on the absorption and pharmacokinetics of rivaroxaban, Int J Clin Pharmacol Ther. juill, vol.51, issue.7, pp.549-61, 2013. ,
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor, Clinical Pharmacology & Therapeutics, vol.78, issue.4, pp.412-421, 2005. ,
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939?an oral, direct Factor Xa inhibitor?after multiple dosing in healthy male subjects, European Journal of Clinical Pharmacology, vol.61, issue.12, pp.873-880, 2005. ,
Pharmacokinetics of BAY 59-7939 ? an oral, direct Factor Xa inhibitor ? in rats and dogs, Xenobiotica, vol.35, issue.9, pp.891-910, 2005. ,
Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban an oral, direct Factor Xa inhibitor in healthy subjects, Int. Journal of Clinical Pharmacology and Therapeutics, vol.45, issue.06, pp.335-344, 2007. ,
In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans, Drug Metabolism and Disposition, vol.37, issue.5, pp.1046-1055, 2009. ,
In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban, Journal of Pharmacology and Experimental Therapeutics, vol.338, issue.1, pp.372-380, 2011. ,
In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition, European Journal of Drug Metabolism and Pharmacokinetics, vol.43, issue.2, pp.183-191, 2017. ,
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects, British Journal of Clinical Pharmacology, vol.76, issue.3, pp.455-466, 2013. ,
Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans, Drug Metabolism and Disposition, vol.37, issue.5, pp.1056-1064, 2009. ,
The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor, The Journal of Clinical Pharmacology, vol.53, issue.3, pp.249-255, 2013. ,
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor, British Journal of Clinical Pharmacology, vol.70, issue.5, pp.703-712, 2010. ,
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor, British Journal of Clinical Pharmacology, vol.76, issue.1, pp.89-98, 2013. ,
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review, Clinical Pharmacokinetics, vol.58, issue.10, pp.1265-1279, 2019. ,
Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa, Am J Cardiovasc Drugs Drugs Devices Interv. avr, vol.16, issue.2, pp.119-146, 2016. ,
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans, Drug Metabolism and Disposition, vol.37, issue.1, pp.74-81, 2008. ,
Apixaban, an oral, direct factor X a inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects, British Journal of Clinical Pharmacology, vol.75, issue.2, pp.476-487, 2013. ,
direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects, Br J Clin Pharmacol. févr, vol.75, issue.2, pp.476-87, 2013. ,
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor X a inhibitor, in healthy subjects, British Journal of Clinical Pharmacology, vol.76, issue.5, pp.776-786, 2013. ,
Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor, European Journal of Drug Metabolism and Pharmacokinetics, vol.36, issue.3, pp.129-139, 2011. ,
Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban, Drug Metabolism and Disposition, vol.41, issue.4, pp.827-835, 2013. ,
Correction to ?In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies?, Drug Metabolism and Disposition, vol.38, issue.5, pp.887-887, 2010. ,
Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor, British Journal of Clinical Pharmacology, vol.79, issue.5, pp.838-846, 2015. ,
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban, The Journal of Clinical Pharmacology, vol.56, issue.5, pp.637-645, 2015. ,
Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis, The Journal of Clinical Pharmacology, vol.56, issue.5, pp.628-636, 2015. ,
Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis, The Journal of Clinical Pharmacology, vol.56, issue.5, pp.628-636, 2015. ,
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum], Clinical Pharmacology: Advances and Applications, p.61, 2014. ,
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nature Medicine, vol.19, issue.4, pp.446-451, 2013. ,
Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa, Blood Advances, vol.1, issue.21, pp.1827-1838, 2017. ,
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity, New England Journal of Medicine, vol.373, issue.25, pp.2413-2424, 2015. ,
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors, New England Journal of Medicine, vol.380, issue.14, pp.1326-1335, 2019. ,
Andexanet Alfa: First Global Approval, Drugs, vol.78, issue.10, pp.1049-1055, 2018. ,
Summary of opinion: Ondexxya,andexanet alfa, Case Medical Research, 2019. ,
Milling TJ, Kaatz S. Preclinical and Clinical Data for Factor Xa and « Universal » Reversal Agents, Am J Med. nov, vol.129, issue.11S, 2016. ,
Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, Journal of Thrombosis and Haemostasis, vol.11, issue.4, pp.756-760, 2013. ,
The laboratory and the direct oral anticoagulants, Blood, vol.121, issue.20, pp.4032-4035, 2013. ,
,
Rechutes de malaria à Plasmodium vivax: traitement court?, Forum Médical Suisse ? Swiss Medical Forum, vol.14, issue.33, pp.326-359, 2014. ,
Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation, TH Open, vol.03, issue.03, pp.e210-e215, 2019. ,
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy), J Am Coll Cardiol. 4 févr, vol.63, issue.4, pp.321-329, 2014. ,
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban, Clinical Pharmacokinetics, vol.53, issue.1, pp.1-16, 2013. ,
Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians, Journal of Thrombosis and Haemostasis, vol.16, issue.2, pp.209-219, 2017. ,
Dabigatran Effects on the International Normalized Ratio, Activated Partial Thromboplastin Time, Thrombin Time, and Fibrinogen: A Multicenter, In Vitro Study, Annals of Pharmacotherapy, vol.46, issue.12, pp.1627-1636, 2012. ,
Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis, Thrombosis Research, vol.135, issue.3, pp.532-536, 2015. ,
Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma, European Journal of Clinical Pharmacology, vol.69, issue.11, pp.1875-1881, 2013. ,
Dabigatran: laboratory monitoring, Pathology, vol.44, issue.6, pp.578-580, 2012. ,
Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate, Thromb Haemost. mai, vol.107, issue.5, pp.985-97, 2012. ,
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity, Thromb Haemost. juin, vol.103, issue.6, pp.1116-1143, 2010. ,
Laboratory Assessment of Novel Oral Anticoagulants: Method Suitability and Variability between Coagulation Laboratories, Clinical Chemistry, vol.59, issue.5, pp.807-814, 2013. ,
Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels, Journal of Thrombosis and Haemostasis, vol.11, issue.8, pp.1493-1502, 2013. ,
Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study, Thrombosis Research, vol.135, issue.5, pp.852-860, 2015. ,
Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM), International Journal of Laboratory Hematology, vol.40, issue.1, pp.84-93, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01958965
Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants, Archives of Pathology & Laboratory Medicine, vol.139, issue.5, pp.665-673, 2015. ,
Diagnostic Accuracy of a Novel Chromogenic Direct Thrombin Inhibitor Assay: Clinical Experiences for Dabigatran Monitoring, Thrombosis and Haemostasis, vol.117, issue.12, pp.2369-2375, 2017. ,
Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis, Journal of the American Heart Association, vol.7, issue.19, p.9807, 2018. ,
Non-VKA oral anticoagulants: an update for the clinical biologists, Annales de biologie clinique, vol.73, issue.3, pp.333-344, 2015. ,
Le Second Congrès International des Pétroles, Revue de Métallurgie, vol.35, issue.2, pp.73-85, 1938. ,
Evaluation of the Prothrombin Time for Measuring Rivaroxaban Plasma Concentrations Using Calibrators and Controls, Clinical and Applied Thrombosis/Hemostasis, vol.18, issue.2, pp.150-158, 2012. ,
The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study, Journal of Thrombosis and Haemostasis, vol.9, issue.1, pp.226-228, 2011. ,
Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A crosssectional pharmacodynamic study based on peak and trough plasma levels, Thromb Haemost. juin, vol.111, issue.6, pp.1133-1173, 2014. ,
How the Direct Oral Anticoagulant Apixaban Affects Thrombin Generation Parameters, Thrombosis Research, vol.135, issue.6, pp.1186-1190, 2015. ,
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents, Journal of Thrombosis and Haemostasis, vol.12, issue.11, pp.1810-1815, 2014. ,
Impact of the Direct Oral Anticoagulants on Activated Clotting Time, Journal of Cardiothoracic and Vascular Anesthesia, vol.31, issue.1, pp.e24-e27, 2017. ,
Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet-Induced Thrombin Generation and Prothrombinase Activity1, The Journal of Clinical Pharmacology, vol.47, issue.11, pp.1398-1407, 2007. ,
Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban, Thromb Haemost, vol.110, issue.4, pp.723-754, 2013. ,
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay, Thromb Haemost. déc, vol.104, issue.6, pp.1263-71, 2010. ,
Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban?an oral, direct and selective factor Xa inhibitor, Journal of Thrombosis and Thrombolysis, vol.32, issue.2, pp.183-187, 2011. ,
Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban, Annals of Pharmacotherapy, vol.49, issue.7, pp.777-783, 2015. ,
Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban, Annals of Pharmacotherapy, vol.52, issue.3, pp.251-256, 2017. ,
Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?, Transfusion and Apheresis Science, vol.55, issue.2, pp.212-215, 2016. ,
Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban, Biochemia medica, vol.30, issue.1, pp.74-82, 2020. ,
Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors, Clinical and Applied Thrombosis/Hemostasis, vol.22, issue.5, pp.423-428, 2016. ,
Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays, International Journal of Laboratory Hematology, vol.38, issue.5, pp.505-513, 2016. ,
Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels, Thrombosis Research, vol.156, pp.36-38, 2017. ,
Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation, TH Open, vol.02, issue.02, pp.e190-e201, 2018. ,
Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation, TH Open, vol.02, issue.02, pp.e190-e201, 2018. ,
Accident ischémique transitoire (AIT) ? Accident vasculaire cérébral (AVC), Mémo-guide infirmier, pp.324-329, 2010. ,
Collège des Enseignants de Neurologie -5ème Edition (Edition Elsevier Masson), disponible via l'ENT de l ,
Nouveau Stade de Bordeaux, Bordeaux, FR, Herzog & de Meuron, 2017. ,
,
, , 2020.
, Mortalité par accident vasculaire cérébral (AVC), 2017 et variation 2000?17 (ou année la plus proche), 2019.
, COVID-19, traçage épidémiologique et éthique médicale, Bulletin de l'Académie Nationale de Médecine, vol.204, issue.7, pp.703-704, 2020.
,
About the Illustrator, Netter's Atlas of Human Embryology, Updated Edition, pp.ix-x, 2012. ,
LAS VEGAS SANDS CORP., a Nevada corporation, Plaintiff, v. UKNOWN REGISTRANTS OF www.wn0000.com, www.wn1111.com, www.wn2222.com, www.wn3333.com, www.wn4444.com, www.wn5555.com, www.wn6666.com, www.wn7777.com, www.wn8888.com, www.wn9999.com, www.112211.com, www.4456888.com, www.4489888.com, www.001148.com, and www.2289888.com, Defendants., Gaming Law Review and Economics, vol.20, issue.10, pp.859-868, 2016. ,
Rapport d'évaluation technologique HAS, Organisation de la prise en charge précoce de l'accident vasculaire cérébral ischémique aigu par thrombectomie mécanique, Juillet, p.133, 2018. ,
, FEVR
https://kujss.iraqjournals.com/pdf_166170_8dd024058ce4abb6c364bec514cecef8.html, Kirkuk University Journal-Scientific Studies, vol.15, issue.2, pp.1-16, 2020. ,
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke, N Engl J Med, vol.26, issue.17, pp.1573-82, 2018. ,
Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials, Journal of Thrombosis and Thrombolysis, vol.46, issue.4, pp.440-450, 2018. ,
,
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct, N Engl J Med, vol.378, issue.1, pp.11-21, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02387070
Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging, New England Journal of Medicine, vol.378, issue.8, pp.708-718, 2018. ,
Correction to: Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association, Stroke, vol.50, issue.12, pp.440-441, 2019. ,
Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13?15 November 2016, European Stroke Journal, vol.2, issue.2, pp.95-102, 2017. ,
Haemorrhagic Transformation after Ischaemic Stroke in Patients Taking Non-vitamin K Antagonist Oral Anticoagulants, Journal of Stroke, vol.19, issue.1, pp.67-76, 2017. ,
The relationship between stroke severity and prior direct oral anticoagulant therapy in patients with acute ischaemic stroke and non-valvular atrial fibrillation, European Journal of Neurology, vol.24, issue.11, pp.1399-1406, 2017. ,
Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants ? A systematic review, PLOS ONE, vol.14, issue.3, p.e0213379, 2019. ,
Intravenous thrombolysis for stroke in patients taking non-VKA oral anticoagulants: an update, Thromb Haemost. août, vol.114, issue.2, pp.440-444, 2015. ,
Safety of Recanalization Therapy in Patients with Acute Ischemic Stroke Under Anticoagulation: A Systematic Review and Meta-Analysis, Journal of Stroke and Cerebrovascular Diseases, vol.27, issue.9, pp.2296-2305, 2018. ,
Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?, International Journal of Stroke, vol.11, issue.7, pp.748-758, 2016. ,
, , p.22
Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol, Journal of Thrombosis and Thrombolysis, vol.41, issue.2, pp.293-300, 2015. ,
Mesurer la qualité pour rationaliser l?hôpital. La genèse des indicateurs de qualité et de sécurité des soins en France, Informations sociales, vol.n° 198, issue.3, p.38, 2018. ,
A PDF upload option for proposal creation, Données, 2016. ,
Prise en charge aiguë des infarctus cérébraux en 2017, La Revue de Médecine Interne, vol.39, issue.6, pp.408-413, 2018. ,
, Littérature commentée juin 2018, La Revue de Médecine Interne, vol.39, issue.6, pp.449-451, 2018.
Sécurité et productivité en hémostase, Revue Francophone des Laboratoires, vol.2013, issue.450, p.18, 2013. ,
Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment, Thrombosis Research, vol.148, pp.107-110, 2016. ,
SERMENT DE GALIEN Je jure, en présence des maîtres de la Faculté et de mes condisciples : ? D'honorer ceux qui m'ont instruite dans les préceptes de mon art et de leur témoigner ma reconnaissance en restant fidèle à leur enseignement ,
intérêt de la santé publique, ma profession avec conscience et de respecter non seulement la législation en vigueur, mais aussi les règles de l'honneur ,
, Le principe de dignité humaine et le personnalisme éthique, Travaux du IXe Congrès International de Philosophie, pp.104-107, 1937.
Utiliser l?analyse fonctionnelle pour favoriser l?insertion professionnelle des jeunes en rupture d?apprentissage, L?Orientation scolaire et professionnelle, issue.45/3, 2016. ,
«Je suis oiseau ; voyez mes ailes...», «Je suis souris : vive les rats !», Caravelle, vol.62, issue.1, pp.179-191, 1994. ,
, Si je constate une violation de mes droits de propriété intellectuelle, que dois-je ou que puis-je faire?, 2004.